http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml?keywords=CTR20240939 Web序号 登记号 试验状态 药物名称 适应症 试验通俗题目; 1: CTR20240939 进行中 尚未招募 硫酸Rimegepant口崩片 每月至少有4次偏头痛发作的、成人发作性偏头痛的预防性治疗
如何查询中国和全球的临床试验信息 - 知乎 - 知乎专栏
WebJan 31, 2024 · The primary end point was the incidence of treatment-emergent adverse events (TEAEs). Results: A total of 93 patients were randomized and received treatment. TEAEs occurred in 55.9% of patients. The incidence of TEAEs was comparable among all the groups. Serious TEAEs occurred in one patient (1.1%), with no deaths observed. Web从网站页面的简介来看,中国临床试验注册中心(Chinese Clinical Trial Registry, ChiCTR)是由卫生部指定代表我国参加世界卫生组织国际临床试验注册平台的国家临床试验注册中心;是世界卫生组织国际临床试验注册平台的一级注册机构,是一个非赢利的学术机构。 3.对于全球的临床试验来说,NIH的U.S. National Library of Medicine所维护的 … iphone adobe illustrator
First in China! Neurophth announced the first patient has been …
http://lib.cpu.edu.cn/65/5c/c1197a91484/page.htm WebSep 23, 2024 · Recurrent and/or metastatic HNSCC without indications for local radical treatment; Cohort 1: Patients who have received previous platinum-based therapy and experienced disease progression or toxic intolerance during or after treatment; Cohort 2: Patients who have received prior platinum-based therapy and immune checkpoint … WebMay 31, 2024 · Background: Pucotenlimab is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb) with a S228P hinge mutation and an engineered Fc domain. Preclinical data suggests that pucotenlimab exerts antitumor effects. In this phase I study, which was prospectively registered on … iphone advantages over android